Danish biotech using its TransCon sustained-release technology for growth-hormone and endocrine-disease drugs.
Danish biotech using its TransCon sustained-release technology for growth-hormone and endocrine-disease drugs.
Sells its medicines itself in the US and Europe to specialist doctors, and relies on partners such as Visen in China, paid through upfront, milestone and royalty payments. Its TransCon technology attaches a drug to a carrier that releases it slowly, giving long-acting dosing, and the same engine is used to build new products.
Moat: narrow (IP / patents, process know-how). Proprietary TransCon prodrug technology gives longer-acting dosing than older daily therapies.
Headquarters: Copenhagen, Denmark · Founded: 2006
Size Ascendis Pharma A/S (ASND) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $16.9B, the 551st largest of 3,085 United States companies the cockpit tracks. Shares closed at $270.33 on 18 Nov 2026.
Performance Over six months the shares gained 12.0%, against +4.4% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 93.8% over the last twelve months (peer median +18.9%); the operating margin is 18.4% (peer median 23.1%).
Valuation It trades at 28.0× forward earnings against a peer median of 23.6× (9th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +152%, so the hurdle is -133 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 11.1 points above its cost of capital (7.0% WACC).
Short interest Short interest is 4.6% of the free float (30 Oct 2026).
Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.40B | $813M | $393M | $288M | $53.8M |
| Revenue growth | — | +107% | +36% | +436% | — |
| Gross profit | $1.27B | $691M | $333M | $225M | $25.7M |
| EBITDA | $278M | -$134M | -$282M | -$472M | -$572M |
| Net income | $1.02B | -$257M | -$409M | -$520M | -$613M |
| Free cash flow | $598M | $51.3M | -$333M | -$508M | -$536M |
| Capital expenditure | $19.7M | $9.58M | $1.54M | $2.64M | $15.2M |
| Total debt | $509M | $1.02B | $887M | $712M | $543M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Ascendis Pharma A/S ASND | $16.9B | +12% | +94% | 18% | 28.0× | 19.2% |
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 11.8× | -0.5% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
| Ipsen IPN.PA | $14.8B | +1% | +14% | 30% | 10.8× | -6.7% |
| BioMarin Pharmaceutical BMRN | $11.9B | +22% | +20% | 19% | 11.2× | 8.2% |
| BridgeBio Pharma BBIO | $15.2B | +14% | +167% | -37% | n/a | n/a |
| Takeda Pharmaceutical 4502.T | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ASND | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.4% | +5.7% | 2nd highest of 21 |
| 6-month return | +12.0% | +4.4% | 7th highest of 21 |
| Distance from 52-week high | -4.2% | -7.2% | 5th highest of 21 |
| Revenue growth (TTM) | +93.8% | +18.9% | 2nd highest of 21 |
| Operating margin | 18.4% | 23.1% | 9th lowest of 21 |
| Forward P/E | 28.0× | 23.6× | 9th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 19.2% | 0.8% | 7th most demanding of 19 |
| Growth delivered (Del g) | +152.4% | +12.3% | highest of 19 |
| Hurdle (Req g minus delivered) | -133.2 pp | -11.2 pp | least demanding of 19 |
| ROIC minus cost of capital | +11.1 pp | +7.2 pp | 7th highest of 21 |
| EV / EBITDA | 58.6× | 16.0× | most expensive of 18 |
| Net debt / EBITDA | -2.1× | 1.1× | 3rd least indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ascendis Pharma A/S ASND | United States | $16.9B | +12% | +94% | 18% | 28.0× | 19.2% | +152.4% |
| Exelixis EXEL | United States | $16.7B | +37% | +9% | 40% | 17.7× | -3.8% | +18.6% |
| Shionogi & 4507.T | Japan | $17.6B | +3% | +46% | 29% | 11.8× | 0.2% | +11.0% |
| Swedish Orphan Biovitrum SOBI.ST | Sweden | $16.1B | +6% | +15% | 30% | 24.1× | -2.1% | +13.1% |
| Jazz Pharmaceuticals Public JAZZ | United States | $15.9B | +4% | +13% | 25% | 9.3× | -2.8% | +12.5% |
| Orion ORNAV.HE | Finland | $15.7B | +41% | +34% | 38% | 23.6× | -6.2% | +11.7% |
| Torrent Pharmaceuticals TORNTPHARM.NS | India | $18.8B | +3% | +42% | 22% | 70.2× | 37.6% | +11.3% |
| Innovent Biologics 1801.HK | Hong Kong | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% | +26.8% |
| PharmaEssentia 6446.TW | Taiwan | $15.0B | +67% | +78% | 40% | 31.9× | 23.7% | +94.8% |
| Yunnan Baiyao 000538.SZ | China | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% | +4.7% |
| Sichuan Biokin Pharmaceutical 688506.SS | China | $14.9B | -7% | +14% | -43% | n/a | n/a | n/a |
| Ipsen IPN.PA | France | $14.8B | +1% | +14% | 30% | 10.8× | -6.7% | +7.2% |
| Alnylam Pharmaceuticals ALNY | United States | $20.0B | -50% | +56% | 20% | 21.2× | 0.5% | +49.8% |
| Laurus Labs LAURUSLABS.NS | India | $13.4B | +73% | +23% | 24% | 76.4× | 51.2% | +7.3% |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.0B | -1% | +44% | -38% | 1,176.1× | 55.3% | +33.6% |
| Zydus Lifesciences ZYDUSLIFE.NS | India | $12.8B | +18% | +24% | 17% | 30.0× | n/a | n/a |
| Sigma Healthcare SIG.AX | Australia | $22.4B | +2% | +209% | 9% | 38.4× | 28.9% | +26.1% |
| Dr. Reddy's Laboratories DRREDDY.NS | India | $12.5B | +5% | -4% | 9% | 32.0× | 30.7% | +12.1% |
| Viatris VTRS | United States | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% | +3.7% |
| Sbp 1177.HK | Hong Kong | $12.2B | +5% | +15% | 30% | 17.5× | -5.7% | +5.4% |
| Recordati REC.MI | Italy | $12.0B | +3% | +8% | 30% | 16.6× | 1.1% | +12.6% |